Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,452 signal articles · 144 in last 24h · 154,112 total before filter · latest 45m ago
144last 24h
877last 7d
147● bullish (7d)
98● bearish (7d)
214publishers
AllMacro210Earnings108M&A125Regulatory22Product21Analyst17
✕ clear all filtersticker: BSXsentiment: bearishSentiment:bullishneutralbearishshow all (incl. clickbait)
Boston Scientific (NYSE:BSX) Surprises With Q2 CY2026 Sales But Quarterly Revenue Guidance Misses Expectations
StockStory57d agobearish
Boston Scientific (NYSE:BSX) Surprises With Q2 CY2026 Sales But Quarterly Revenue Guidance Misses Expectations

Medical device company Boston Scientific (NYSE:BSX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.5% year on year to $5.44 billion. On the other hand, next quarter’s revenue guidance of $5.27 billion was less impressive, coming in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.86 per share was 3.8% above analysts’ consensus estimates.